1. A single‐ and multiple‐ascending dose study to evaluate the safety and pharmacokinetics of oral PU‐AD, an epichaperome inhibitor to treat Alzheimer's disease: Human/Trial design. (7th December 2020) Authors: Silverman, Michael; Wallner, Barbara; Key, Cassandra; Duggan, Susan M.; Reynolds, Laurie Journal: Alzheimer's & dementia Issue: Volume 16(2020)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects. Issue 7 (4th May 2022) Authors: Gu, Kenan; Ruff, Dennis; Key, Cassandra; Thompson, Marissa; Jiang, Shoshanna; Sandison, Taylor; Flanagan, Shawn Journal: Clinical and translational science Issue: Volume 15:Issue 7(2022) Page Start: 1592 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗